Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

(2020) Henna Kasanen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

(2019) Jinyu Zhang et al.   Journal for ImmunoTherapy of Cancer

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

(2018) Kevin C. Barry et al.   NATURE MEDICINE

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

(2018) Lucas Ferrari de Andrade et al.   SCIENCE

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity

(2018) Elise Alspach et al.   Cold Spring Harbor Perspectives in Biology

Advanced stage melanoma therapies: Detailing the present and exploring the future

(2018) Chelsea Luther et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

(2018) Hansol Lee et al.   OncoImmunology

Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade

(2017) Alejandro López-Soto et al.   OncoImmunology

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

(2017) Cristina Maccalli et al.   OncoImmunology

What does PD-L1 positive or negative mean?

(2016) Antoni Ribas et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arginine dependence of tumor cells: targeting a chink in cancer’s armor

(2016) M D Patil et al.   ONCOGENE

Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors

(2015) S. Lu et al.   CLINICAL CANCER RESEARCH

Comparative genomics of the NKG2D ligand gene family

(2015) Masanori Kasahara et al.   IMMUNOLOGICAL REVIEWS

Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype

(2015) Gang Xiao et al.   Journal of Hematology & Oncology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC

(2015) Fahmin Basher et al.   Oncotarget

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Reactive Oxygen Species– and DNA Damage Response–Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1

(2014) Alessandra Soriani et al.   JOURNAL OF IMMUNOLOGY

Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention

(2014) Aroa Baragaño Raneros et al.   OncoImmunology

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

(2013) Y. Liao et al.   BIOINFORMATICS

Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis

(2013) Gang Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

(2012) Esther M de Kruijf et al.   BMC CANCER

Cutting Edge: A Novel Mechanism Bridging Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors on NK Cells

(2012) S.-H. Lee et al.   JOURNAL OF IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice

(2011) Kazuyoshi Takeda et al.   JOURNAL OF LEUKOCYTE BIOLOGY

ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients

(2010) Roger W. McGilvray et al.   INTERNATIONAL JOURNAL OF CANCER

NKG2D Initiates Caspase-Mediated CD3  Degradation and Lymphocyte Receptor Impairments Associated with Human Cancer and Autoimmune Disease

(2010) N. Hanaoka et al.   JOURNAL OF IMMUNOLOGY

The role of murine models of prostate cancer in drug target discovery and validation

(2009) Imran Ahmad et al.   Expert Opinion on Drug Discovery

Soluble NKG2D ligands: prevalence, release, and functional impact

(2008) Helmut Rainer Salih   Frontiers in Bioscience-Landmark

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA